Webhttp://www.cytokinetics.com Industries Biotechnology Research Company size 201-500 employees Headquarters South San Francisco, California Type Public Company Founded 1998 Specialties Heart... WebCytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.
Cytokinetics Stock Trading Halted Today Cytokinetics, Inc.
WebFeb 27, 2024 · On Feb. 28, the FDA is set to decide on Cytokinetics ’ omecamtiv mecarbil (OM), a novel, selective cardiac myosin activator being evaluated for heart failure with reduced ejection fraction. The regulatory agency accepted the New Drug Application for OM in February 2024 and initially set a target action date of Nov. 30, 2024. WebApr 6, 2024 · Cytokinetics started at overweight with $58 stock price target at J.P. Morgan. Dec. 10, 2024 at 6:59 a.m. ET by Tomi Kilgore. Biotech and Pharma Cytokinetics Stock Is Surging. Heart-Drug Results ... imany full album
Cytokinetics LinkedIn
WebBrowse the 27 Philadelphia Jobs at Cytokinetics and find out what best fits your career goals. WebFeb 23, 2024 · Pivotal Trial to Assess the Potential of Aficamten to Improve Exercise Capacity, Heart Failure Symptoms and Functional Class SOUTH SAN FRANCISCO, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of … WebSep 27, 2024 · View Paul Uricchio's email address (p*****@cytoki***.com) and phone number. Paul works at Cytokinetics as Director of Marketing, Hospital. Paul is based out of Greater Philadelphia and works in the Biotechnology industry. imany lyrics